# Incidental detection of PDAC via 18F-PSMA PET/CT in a patient with recurrent prostate cancer. A case report

## TL;DR

A PET/CT scan for prostate cancer recurrence accidentally detected pancreatic cancer, highlighting PSMA's potential for dual diagnostic and therapeutic use.

## Contribution

This case report highlights the incidental detection of PDAC using PSMA PET/CT and its potential for theranostic applications.

## Key findings

- PSMA PET/CT detected PDAC in a patient with recurrent prostate cancer.
- PSMA overexpression in PDAC suggests potential for theranostic applications.

## Abstract

Prostate specific membrane antigen (PSMA) is a type II transmembrane protein overexpressed in the neovasculature of some pancreatic ductal adenocarcinoma (PDAC). PET/CT can detect this expression and has now become an essential tool in this context. However, this antigen can also be expressed by other neoplasms. While this may create diagnostic uncertainty, it could also open therapeutic opportunities.

Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC.

A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon.

Prostate-specific membrane antigen can be overexpressed in PDACs. This finding may offer potential for theranostic applications